Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GAIA (Gaianet) fluctuated by 40.1% within 24 hours: price rebounded from $0.00764 to $0.0107, trading volume surged to around $270,000

GAIA (Gaianet) fluctuated by 40.1% within 24 hours: price rebounded from $0.00764 to $0.0107, trading volume surged to around $270,000

Bitget PulseBitget Pulse2026/05/13 06:54
Show original
By:Bitget Pulse

Brief Overview of Volatility

In the past 24 hours, GAIA's price hit a low of $0.00764 and a high of $0.0107. The current quoted price is $0.0107, with an overall price fluctuation amplitude of 40.1%. The 24-hour trading volume is approximately $269,506, down 8.10% from the previous day, but it still remains active among small-cap tokens. The circulating supply is around 170 million, with a market capitalization of approximately $1.3 million.

Brief Analysis of Abnormal Movements

- CoinMarketCap updated the GAIA token unlock event (Token Unlocks) on May 12, 2026, which may trigger short-term trading activity and price volatility.

- No verifiable data from official announcements, major news reports, significant on-chain whale transfers, or net capital inflows were found in the past 24 hours. The main driver comes from a natural rebound under increased trading volume.

Market Opinion and Outlook

There is limited discussion about GAIA in the X platform community. A few users have included it in their personal portfolios, without noticeable enthusiasm or mainstream predictions. Price prediction models suggest a neutral trend by the end of 2026, with an estimated price of around $0.0081, emphasizing high market volatility and recommending attention to the impact of future unlocks.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs Upgrades CoreWeave to "Buy": Market Overestimates Financing Costs and Underestimates Computing Fee Capabilities

Goldman Sachs has upgraded CoreWeave’s rating from “Neutral” to “Buy,” with a target price of $106, offering approximately 73% upside from the latest closing price of $61.39. Goldman Sachs believes the market is overly concerned about CoreWeave’s financing costs but underestimates its charging potential for computing power: asset-backed financing supported by GPU and customer contracts is not entirely tied to corporate bond yields. Additionally, annual revenue per megawatt is expected to rise from the current $10 million to $13 million, improving investment returns.

华尔街见闻•2026/10/19 13:01
Goldman Sachs Upgrades CoreWeave to "Buy": Market Overestimates Financing Costs and Underestimates Computing Fee Capabilities

AI Credit Pressure Surfaces: CoreWeave Bonds Become the New Barometer for the US Stock Market

CoreWeave's unsecured bonds have replaced Nvidia as the market's "beta barometer" for measuring AI trades. The bonds’ yields have surged past 16% and CDS spreads have soared, highlighting the high dependence of emerging cloud computing companies on debt financing and their funding gap risks. Credit pressures are spreading from infrastructure to equity markets, and the main focus of AI trading has shifted from computing power demand to financing costs and sustainability.

华尔街见闻•2026/10/19 12:46
AI Credit Pressure Surfaces: CoreWeave Bonds Become the New Barometer for the US Stock Market

GSK (GSK.US), Inovio (INO.US), and Agios (AGIO.US) cluster for review, US innovative drugs welcome FDA approval window

The FDA will intensively decide on several new drugs in the next two weeks: GSK's functional cure therapy for hepatitis B, Inovio's rare disease therapy, Agios's new drug for sickle cell disease, and Sun Pharma's application for expanded indications.

智通财经•2026/10/19 11:37
GSK (GSK.US), Inovio (INO.US), and Agios (AGIO.US) cluster for review, US innovative drugs welcome FDA approval window

After the Philadelphia Semiconductor Index and Nasdaq plunged, Morgan Stanley called to "get ready to increase positions"

Michael Wilson from Morgan Stanley stated that as the significant correction trajectory in most stock markets over the past few months is about to end, investors should be prepared to increase the risk exposure in their portfolios.

智通财经•2026/10/19 11:18